Does impaired gastric acidity or acid-suppressing therapy reduce absorption of oral levothyroxine?

Evidence-based research confirms that gastric acidity is a critical requirement for the effective absorption of oral thyroid hormone, particularly the standard tablet form of levothyroxine (L-T4).

Clinical effectiveness and dosing

The use of acid-suppressing medications, especially proton pump inhibitors (PPIs) such as omeprazole, is strongly associated with reduced bioavailability of thyroid hormone. Clinical studies have demonstrated that patients initiating PPI therapy often experience a significant rise in thyroid-stimulating hormone (TSH), indicating a drop in circulating thyroid hormone levels.

• Dose adjustments: Patients on concurrent PPI therapy frequently require a dose increase of approximately 22% to 37% to maintain euthyroidism.
• Gastric pathology: Beyond medications, clinical conditions that impair acid production—such as Helicobacter pylori infection, atrophic gastritis, and achlorhydria—similarly increase L-T4 requirements by 22% to 34%. Eradication of H. pylori has been shown to restore normal absorption and reduce the necessary hormone dose.

Mechanistic explanations

The interaction is primarily due to the pH-dependent nature of thyroid hormone dissolution.

• Dissolution as a rate-limiting step: Levothyroxine is a lipophilic molecule with low solubility. It requires an acidic environment (optimal pH ~2.0–2.3) to dissolve in the stomach. Once dissolved, it is absorbed in the jejunum and ileum.
• Impact of elevated pH: When gastric acidity is reduced (pH > 3.0), the tablet does not fully disintegrate or dissolve, leading to incomplete absorption.
• Formulation differences: This mechanism is specific to tablet formulations. Liquid L-T4 and soft-gel capsules bypass the acid-dependent dissolution phase and have been shown to maintain stable absorption regardless of gastric pH.

Bottom line

Acid-suppressing therapy and impaired gastric acidity significantly reduce the absorption of thyroid hormone tablets, often leading to persistently low circulating levels and requiring a 20–40% increase in dosage. Patients with refractory hypothyroidism should be evaluated for gastric conditions or considered for liquid/soft-gel formulations.